MAPT and Cognitive impairment: Recently, a multiscience working group of European researchers used a structured, well‐organized, and comprehensive methodology based on an extensive literature search, prioritization of clinical questions, and grading of the quality of evidence to publish a number of clinical markers, such as cerebrospinal fluid (CSF) Aβ42, tau protein, and phosphorylated tau protein, which can identify mild cognitive impairment or AD.15